Guo Yongren's mind couldn't help but come to the information that he accidentally came across while searching on the Internet. The bloody history of the development of Chinese traditional medicine is a complete tragedy, pitiful, sad, deplorable, and hateful.
According to statistics in 2014, the global traditional Chinese medicine market was about 100 billion in 2014, and my country only accounted for 9%. This data comes from the statistics of a foreign company. There may be a deviation, but it will not be too large. Currently, it is recognized in the industry that South Korea, Japan, Foreign companies such as the United States directly monopolize about 90% of the international market for proprietary Chinese medicines.
According to statistics, in the overseas traditional Chinese medicine market, China holds only 0.3% patent rights, while Japan and South Korea account for more than 70% of traditional Chinese medicine patents.
Tsumura Pharmaceutical, Japan's largest Kampo pharmaceutical company, has established more than 70 GAP medicinal material planting bases in my country, while Tongrentang, the traditional Chinese medicine company with the most GAP bases in my country, only has 8. The gap in number is very large.
As of the end of May 2014, my country has certified a total of 152 GAP planting bases for 66 Chinese herbal medicine varieties, of which more than 70 GAP medicinal planting bases are controlled by Japan-Tsumura Pharmaceutical. It is unknown whether the remaining 80 or so GAP medicinal planting bases are still in use. How much is controlled by Japan or other countries.
GAP refers to the "Production Quality Management Regulations for Traditional Chinese Medicinal Materials", which stipulates that research and development, production and management should be carried out in accordance with internationally recognized standards.
In addition to the medicinal materials produced by Japan's GAP medicinal material planting base and exported to Japan, a large amount of high-quality raw materials of Chinese medicinal materials that do not exceed the standard for heavy metals, pesticides do not exceed the standard and are not vulcanized are also exported to Japan in large quantities.
At the same time, Japanese pharmaceutical companies strictly control the quality of traditional Chinese medicine raw materials and resolutely do not allow heavy metals that exceed standards, pesticides that exceed standards, or other unqualified Chinese medicine materials to enter their production workshops.
A Japanese pharmaceutical company controls nearly half of China's GAP medicinal planting bases. This is a terrifying thing.
Japan's strategy on traditional Chinese medicine is to clearly state that "the prescriptions originate from China and the medicinal materials are obtained from China. When Chinese traditional medicine companies are still intoxicated with themselves, they close the door to the internationalization of Chinese traditional medicine and maximize their share of the international traditional Chinese medicine market."
."
Because Japanese pharmaceutical companies understand that the origin of traditional Chinese medicine is China, but Chinese traditional medicine does not have global competitiveness, Japanese pharmaceutical companies rush to acquire patents for some famous Chinese traditional medicine formulas in the European and American markets. For example, Imperial Pharmaceuticals of Japan will add flavored Xiaoyaosan, Angelica sinensis, etc.
Patent medicines such as peony decoction, Guizhi Fuling Pills, ulcerative colitis treatment drugs, etc. have been registered for US patents
Due to the existence of patents, European and American pharmaceutical companies with strong intellectual property rights cannot produce, and at the same time, Chinese pharmaceutical companies in the country of origin cannot produce. The management methods of Japanese pharmaceutical companies are really clever.
This piece of information slowly emerged in Guo Yongren's mind. This can be said to be a pain in the hearts of all Chinese people, but now that he is here, these must be taken back. The monopoly of traditional Chinese medicine must belong to the protective umbrella. This is not the case.
We had to discuss it, Guo Yongren made up his mind.
"Okay Naomi, I have to go to Tokyo tomorrow, let's go together," Guo Yongren said directly. Hosokawa Naomi had no doubt that he was there and nodded in agreement.
The next day, Guo Yongren returned to Tokyo with Guan Du, Wang Dajun, and Naomi Hosokawa. Nagoya was left in charge of Takahashi Shogo. There were not many things, and Takahashi Shogo and the others had no problems at all.
When they arrived in Tokyo, Guo Yongren separated from Naomi Hosokawa. When Guo Yongren returned to the hotel, he went directly to find Kandu and asked Kandu to get a feel for the foundation of Ohno Traditional Chinese Medicine Company, which declared bankruptcy, and at the same time learn about the current status of Japanese traditional Chinese medicine companies.
What is the current situation like? I gave Guan Du a check and asked Guan Du to do the work.
Money makes it easier to do things. This principle is the same everywhere. After spending hundreds of thousands of dollars, a detailed report was placed in front of Guo Yongren in a week. Guo Yongren looked at it seriously. The Japanese traditional Chinese medicine companies in this era were not doing well.
Things are getting better. It can be said that we are struggling to survive. There are many companies that cannot publish new books, and many small companies have gone bankrupt. It is a good time to buy at the bottom.
The information was written in great detail. Each of these companies had their own unique products. Guo Yongren thought about it and called Guan Du over, and the two of them started discussing in the room.
Passing the enterprise directory to Guan Du, "Everything circled here, buy it all," Guo Yongren said directly, not considering other things at all, just take them first, not to mention that the acquisition cost is not high now.
Guan Du took a look and saw that there were more than a dozen companies, all of which were pharmaceutical factories. They were not big in scale, and the life of the companies was not easy. What was the purpose of acquiring a pharmaceutical company? Moreover, it was a traditional Chinese medicine company. Nowadays, people who are sick take Western medicine.
, it works quickly, and it also cures diseases. It is of little value. He looked at Guo Yongren a little puzzled.
"Don't ask why, just do it. Take this, the sooner the better." Guo Yongren said directly. He was not in the mood to explain now. At the same time, he gave Guan Du a cash check of US$500,000 as funds for the event. Guan Du nodded.
, Guo Yongren is the boss, and the boss can just make the decision himself.
I went out with the catalog and began to investigate more detailed information for negotiation. The boss decided that the sooner the better, so there must be enough information. He commissioned several well-known private detectives to start the operation.
Guan Du leaves early and comes back late every day. Guo Yongren basically stays in the hotel and does not go out. There are no mobile phones yet, so it is very inconvenient to contact him, so he does not go there and keeps in touch with Guan Du at all times.
In just ten days, the first company was completed, and then almost one company a day. In less than a month, all the companies on Guo Yongren's list were acquired.
Immediately afterwards, Guo Yongren did not start to integrate. Instead, he immediately began to apply for patents on the formulas and names of traditional Chinese medicine products held by these companies. He was not afraid of spending money. A patent costs a lot of money, but this money must be spent. Guo Yongren is a bit more
He didn't care, Guan Du was as tired as a donkey during this period, and the eyes he looked at Guo Yongren every day were full of deep resentment.
After all the applications for patent materials were submitted, Guo Yongren and Guan Du breathed a sigh of relief. Guo Yongren, in particular, spent money to hire a lobbying company in order to ensure smooth implementation. Japan was modeled after the United States, and the price was not cheap.
With $800,000 to ensure smooth approval of the patent, Guo Yongren paid directly and signed an agreement without saying a word, letting the Japanese lobbying company operate it.
After all these things were done, Guo Yongren began to integrate these more than a dozen Chinese medicine companies and began to inventory all the assets. After the inventory, Guo Yongren smiled. This acquisition only cost more than 30 million US dollars, and he could see the harvest.
At that time, Guo Yongren felt that he was so lucky.
More than a dozen companies have built eight ready-made buildings in Tokyo, with the highest being 16 floors and the lowest being four floors, as well as factories in the suburbs and other assets. You must know that it is only 1981, and Tokyo is one of the cities with the highest housing prices in the world.
First, it is simply unimaginable how much these will appreciate in the future.
Another thing that makes Guo Yongren feel gratified is that these dozen companies are basically family-managed. After Guo Yongren’s acquisition, many senior executives left voluntarily. These people do not have much ability, but they occupy high positions.
, now it’s better, a lot of space has been freed up.
Guo Yongren began another round of intense interviews, while looking through their resumes. It took a full week before the candidates for the umbrella medical department were confirmed, and there were many people.
The sixteen-story building in a good location was officially renamed the Umbrella Pharmaceutical Building and began new renovations. It will be the headquarters of a Japanese pharmaceutical company.
Yoshida Eisuke: Appointed as General Manager of Umbrella Pharmaceuticals (Japan Branch)
Hideyuki Tanaka: Appointed as Deputy General Manager of Umbrella Pharmaceuticals (Japan Branch)
Joji Ida: Appointed as Deputy General Manager of Umbrella Pharmaceuticals (Japan Branch)
Kaede Hasegawa: Appointed as Administrative Department Manager of Umbrella Pharmaceuticals (Japan Branch)
Baokan Keshou: Appointed as the manager of the medicinal materials purchasing department of Umbrella Pharmaceuticals Company (Japan Branch)
Yuji Ohno: Appointed as Deputy Manager of the Pharmaceutical Purchasing Department of Umbrella Pharmaceuticals (Japan Branch)
Mitsui Yan Hui: Appointed as deputy manager of the medicinal materials purchasing department of Umbrella Pharmaceuticals (Japan Branch)
Professor Tomoko Saihei: Appointed as Director of Scientific Research Department of Umbrella Pharmaceuticals Corporation (Japan Branch)
Professor Chenpachi Mu: Appointed as Director of Scientific Research Department of Umbrella Pharmaceuticals Corporation (Japan Branch)
Professor Shunaka Sato: Appointed as Director of Scientific Research Department of Umbrella Pharmaceuticals Corporation (Japan Branch)
Shuichi Minamino: Appointed as Sales Director of Umbrella Pharmaceuticals (Japan Branch)
Ryui Miyazaki: Appointed as Deputy Director of Sales Department of Umbrella Pharmaceuticals (Japan Branch)
Kiyoshi Kobayashi: Appointed as Deputy Director of Sales Department of Umbrella Pharmaceuticals (Japan Branch)
Nakajima Nakahiko: Appointed as Head of Quality Control Department of Umbrella Pharmaceuticals (Japan Branch)
Yuehua Ren: Appointed as deputy director of the quality control department of Umbrella Pharmaceuticals (Japan Branch)
Takuya Hanazawa: Appointed as deputy director of the quality control department of Umbrella Pharmaceuticals (Japan Branch)
Ryuichi Horibe: Appointed as Deputy Director of the Quality Control Department of Umbrella Pharmaceuticals (Japan Branch)
Kappei Yamaguchi: Appointed as Marketing Manager of Umbrella Pharmaceuticals (Japan Branch)
Kazuhiko Inoue: Appointed as deputy manager of the marketing department of Umbrella Pharmaceuticals (Japan Branch)
Nagato Takashi: appointed as deputy manager of the marketing department of Umbrella Pharmaceuticals (Japan Branch)
It is not difficult to see from this appointment that Guo Yongren has put great effort into the quality control of his products. Other departments are basically equipped with one principal and two assistants, except for the quality control department, which is equipped with one principal and three assistants. Product quality is the survival of the enterprise.
The foundation of this point, no matter how hard we work, it cannot be overemphasized.
At the same time, Guo Yongren transferred two financial officers from Hong Kong to form the financial department of the umbrella pharmaceutical company. The international accounting firm PricewaterhouseCoopers served as the company's contracted audit agency, and the Japanese branch of the American Felson Law Firm served as the legal review agency of the pharmaceutical company.
All contracts that are not signed and confirmed by the legal review department are illegal contracts.